Schistosomiasis is a parasitic disease caused by Schistosoma worms. The disease is transmitted to humans through contact with water contaminated with the parasite's eggs. The infection can cause fever, abdominal pain, diarrhea, and anemia. In severe cases, it can lead to bladder cancer or kidney failure. Praziquantel is the most common drug used for treatment of schistosomiasis in adults and children over 2 years old. Oxamniquine is also used for treatment of schistosomiasis in adults and children over 2 years old who are infected with S. haematobium or S. mansoni but not S. japonicum or S. mekongi infections.
Some Of The Growth Factors Of This Market:
- Schistosomiasis is a parasitic disease that affects over 200 million people worldwide.
- The World Health Organization estimates that schistosomiasis causes more than 200,000 deaths annually.
- Schistosomiasis is caused by a parasite called Schistosoma and can be transmitted through contact with contaminated water or by the release of eggs from infected snails into the water supply.
- The WHO has set 2020 as the target date for eliminating schistosomiasis as a public health problem.
- There are currently no vaccines or drugs to treat schistosomiasis.
Industry Growth Insights published a new data on “Drugs for Schistosomiasis Market”. The research report is titled “Drugs for Schistosomiasis Market research by Types (Praziquantel, Oxamniquine, Other), By Applications (S. haematobium, S. mansoni, S. japonicum, S. mekongi, S. intercalatum), By Players/Companies Shin Poong, Merck, Bayer, EIPICO, Chandra Bhagat Pharma, Taj Pharmaceuticals”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Drugs for Schistosomiasis Market Research Report
By Type
Praziquantel, Oxamniquine, Other
By Application
S. haematobium, S. mansoni, S. japonicum, S. mekongi, S. intercalatum
By Companies
Shin Poong, Merck, Bayer, EIPICO, Chandra Bhagat Pharma, Taj Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
Global Drugs for Schistosomiasis Market Report Segments:
The global Drugs for Schistosomiasis market is segmented on the basis of:
Types
Praziquantel, Oxamniquine, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
S. haematobium, S. mansoni, S. japonicum, S. mekongi, S. intercalatum
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Shin Poong
- Merck
- Bayer
- EIPICO
- Chandra Bhagat Pharma
- Taj Pharmaceuticals
Highlights of The Drugs for Schistosomiasis Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Praziquantel
- Oxamniquine
- Other
- By Application:
- S. haematobium
- S. mansoni
- S. japonicum
- S. mekongi
- S. intercalatum
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Drugs for Schistosomiasis Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Drugs for schistosomiasis are medications that help to treat the disease. These drugs can be taken by mouth, injected into a vein, or applied topically. They work by killing the parasites that cause schistosomiasis.
Some of the key players operating in the drugs for schistosomiasis market are Shin Poong, Merck, Bayer, EIPICO, Chandra Bhagat Pharma, Taj Pharmaceuticals.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Drugs for Schistosomiasis Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Drugs for Schistosomiasis Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Drugs for Schistosomiasis Market - Supply Chain
4.5. Global Drugs for Schistosomiasis Market Forecast
4.5.1. Drugs for Schistosomiasis Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Drugs for Schistosomiasis Market Size (000 Units) and Y-o-Y Growth
4.5.3. Drugs for Schistosomiasis Market Absolute $ Opportunity
5. Global Drugs for Schistosomiasis Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Drugs for Schistosomiasis Market Size and Volume Forecast by Type
5.3.1. Praziquantel
5.3.2. Oxamniquine
5.3.3. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Drugs for Schistosomiasis Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Drugs for Schistosomiasis Market Size and Volume Forecast by Application
6.3.1. S. haematobium
6.3.2. S. mansoni
6.3.3. S. japonicum
6.3.4. S. mekongi
6.3.5. S. intercalatum
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Drugs for Schistosomiasis Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Drugs for Schistosomiasis Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Drugs for Schistosomiasis Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Drugs for Schistosomiasis Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Drugs for Schistosomiasis Demand Share Forecast, 2019-2026
9. North America Drugs for Schistosomiasis Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Drugs for Schistosomiasis Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Drugs for Schistosomiasis Market Size and Volume Forecast by Application
9.4.1. S. haematobium
9.4.2. S. mansoni
9.4.3. S. japonicum
9.4.4. S. mekongi
9.4.5. S. intercalatum
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Drugs for Schistosomiasis Market Size and Volume Forecast by Type
9.7.1. Praziquantel
9.7.2. Oxamniquine
9.7.3. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Drugs for Schistosomiasis Demand Share Forecast, 2019-2026
10. Latin America Drugs for Schistosomiasis Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Drugs for Schistosomiasis Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Drugs for Schistosomiasis Market Size and Volume Forecast by Application
10.4.1. S. haematobium
10.4.2. S. mansoni
10.4.3. S. japonicum
10.4.4. S. mekongi
10.4.5. S. intercalatum
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Drugs for Schistosomiasis Market Size and Volume Forecast by Type
10.7.1. Praziquantel
10.7.2. Oxamniquine
10.7.3. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Drugs for Schistosomiasis Demand Share Forecast, 2019-2026
11. Europe Drugs for Schistosomiasis Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Drugs for Schistosomiasis Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Drugs for Schistosomiasis Market Size and Volume Forecast by Application
11.4.1. S. haematobium
11.4.2. S. mansoni
11.4.3. S. japonicum
11.4.4. S. mekongi
11.4.5. S. intercalatum
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Drugs for Schistosomiasis Market Size and Volume Forecast by Type
11.7.1. Praziquantel
11.7.2. Oxamniquine
11.7.3. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Drugs for Schistosomiasis Demand Share, 2019-2026
12. Asia Pacific Drugs for Schistosomiasis Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Drugs for Schistosomiasis Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Drugs for Schistosomiasis Market Size and Volume Forecast by Application
12.4.1. S. haematobium
12.4.2. S. mansoni
12.4.3. S. japonicum
12.4.4. S. mekongi
12.4.5. S. intercalatum
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Drugs for Schistosomiasis Market Size and Volume Forecast by Type
12.7.1. Praziquantel
12.7.2. Oxamniquine
12.7.3. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Drugs for Schistosomiasis Demand Share, 2019-2026
13. Middle East & Africa Drugs for Schistosomiasis Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Drugs for Schistosomiasis Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Drugs for Schistosomiasis Market Size and Volume Forecast by Application
13.4.1. S. haematobium
13.4.2. S. mansoni
13.4.3. S. japonicum
13.4.4. S. mekongi
13.4.5. S. intercalatum
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Drugs for Schistosomiasis Market Size and Volume Forecast by Type
13.7.1. Praziquantel
13.7.2. Oxamniquine
13.7.3. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Drugs for Schistosomiasis Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Drugs for Schistosomiasis Market: Market Share Analysis
14.2. Drugs for Schistosomiasis Distributors and Customers
14.3. Drugs for Schistosomiasis Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Shin Poong
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Merck
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Bayer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. EIPICO
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Chandra Bhagat Pharma
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Taj Pharmaceuticals
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
